Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epalolitoworelimab and Lenvatinib in Perioperative Treatment of ccRCC
NCT07741617Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in clear cell renal cell carcinoma (ccRCC), sponsored by Nanjing Drum-Tower Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07741617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741617.